cd7 car-t cell

Cell therapyexperimental

Clinical trial activity

42 trials · 35 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2019 (NCT04004637)

Timeline

2010s

Jan 1, 2019
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2021
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

CD7Immunity, passive
CD7 immunity, passive
- T-cell antigen CD7 (CD7) ↗

Chemistry & pharmacology

Oral

Parenteral

Topical

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT07244380	Phase 2	Nov 28, 2025	Hebei Senlang Biotechnology Inc., Ltd., Jiao Tong University, Peking University
NCT07188610	Phase 2	Oct 1, 2025	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NCT07201727	Early Phase 1 (Phase 1)	Sep 30, 2025	China Academy of Chinese Medical Sciences
NCT07117175	Early Phase 1 (Phase 1)	Sep 1, 2025	Jiao Tong University
NCT07117305	Phase 1/Phase 2 (Phase 2)	Sep 1, 2025	Government of China, Zhengzhou University
NCT07109518	Phase 1	Jun 28, 2025	China Academy of Chinese Medical Sciences
NCT07008872	N/A	Jun 1, 2025	Government of China, Tianjin Medical University
NCT07106723	Phase 2	Jun 1, 2025	China Academy of Chinese Medical Sciences, Government of China
NCT06925464	Phase 1/Phase 2 (Phase 2)	Apr 1, 2025	Government of China, Jiao Tong University, Shanghai Liquan Hospital
NCT06871644	N/A	Mar 18, 2025	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NCT06787560	Early Phase 1 (Phase 1)	Jan 31, 2025	Yake Biotechnology Ltd., Zhejiang University
NCT06769191	Early Phase 1 (Phase 1)	Jan 30, 2025	Yake Biotechnology Ltd., Zhejiang University
NCT06720324	Phase 1/Phase 2 (Phase 2)	Dec 31, 2024	Government of China, Huazhong University of Science and Technology
NCT06633328	Early Phase 1 (Phase 1)	Oct 20, 2024	Yake Biotechnology Ltd., Zhejiang University
NCT06420076	Phase 1/Phase 2 (Phase 2)	Jul 10, 2024	Essen Biotech
NCT06316427	Phase 1/Phase 2 (Phase 2)	Mar 22, 2024	Government of China
NCT06585345	Phase 1/Phase 2 (Phase 2)	Feb 18, 2024	People's Liberation Army of China
NCT05995028	Phase 1	Oct 31, 2023	Shenzhen Geno-Immune Medical Institute
NCT05909527	Phase 1/Phase 2 (Phase 2)	May 1, 2023	Guangzhou Bio-gene Technology Co., Ltd., Hebei University
NCT05827835	Phase 2	Apr 30, 2023	Yake Biotechnology Ltd., Zhejiang University

Showing 20 of 42 trials

Page 1 / 3

Organizations

Research & Development (35)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
PersonGen BioTherapeutics (Suzhou) Co., Ltd.	For profit	8	6	3	2019
Government of China	Government	7	2	3	2021
Yake Biotechnology Ltd.	Government	7	0	2	2020
Zhejiang University	Academic/Hospital	7	6	2	2020
Jiao Tong University	Academic/Hospital	5	2	2	2020
Peking University	Academic/Hospital	4	0	2	2020
Zhengzhou University	Academic/Hospital	4	1	2	2019
China Academy of Chinese Medical Sciences	Academic/Hospital	3	3	2	2025
Hebei Senlang Biotechnology Inc., Ltd.	For profit	3	3	2	2020
Huazhong University of Science and Technology	Academic/Hospital	3	2	2	2021
People's Liberation Army of China	Government	3	3	2	2020
Soochow University	Academic/Hospital	3	2	2	2021
Beijing Boren Hospital	Academic/Hospital	2	2	2	2021
Chinese Academy of Medical Sciences	Academic/Hospital	2	1	2	2021
Hebei University	Academic/Hospital	2	0	2	2022
iCell Gene Therapeutics	For profit	2	2	1	2020
Shenzhen Geno-Immune Medical Institute	Academic/Hospital	2	2	2	2019
Anhui Medical University	Academic/Hospital	1	0	1	2020
Bioceltech Therapeutics, Ltd.	For profit	1	1	1	2022
Central South University	Academic/Hospital	1	0	1	2020

35 organizations

Page 1 / 2